EcoDrugPlus

Estrogen Receptor 2

Ensembl ID : ENSBTAG00000004498
Gene Symbol: ESR2
12 Enzyme and pathways 5 Cross references
285 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSBTAG00000010392
Gene Symbol: ESRRG
4 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Exportin 1

Ensembl ID : ENSBTAG00000013254
Gene Symbol: XPO1
36 Enzyme and pathways 5 Cross references
308 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSBTAG00000003948
Gene Symbol: FDPS
4 Cross references
280 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSBTAG00000012432
Gene Symbol: FDFT1
4 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSBTAG00000003201
Gene Symbol: FNTA
13 Enzyme and pathways 5 Cross references
228 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSBTAG00000005897
Gene Symbol: FNTB
9 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSBTAG00000007507
Gene Symbol: FAAH
4 Enzyme and pathways 5 Cross references
143 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSBTAG00000008140
Gene Symbol: FAP
5 Cross references
139 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSBTAG00000005691
Gene Symbol: FGF2
58 Enzyme and pathways 5 Cross references
129 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSBTAG00000015457
Gene Symbol: FGFR1
28 Enzyme and pathways 5 Cross references
305 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSBTAG00000014064
Gene Symbol: FGFR2
27 Enzyme and pathways 5 Cross references
230 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).